These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23439802)

  • 1. Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.
    Chang JS; Shin J; Kim HS; Kim KH; Shin JA; Yoon KH; Cha BY; Son HY; Cho JH
    Diabetes Metab J; 2013 Feb; 37(1):72-80. PubMed ID: 23439802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 3. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan.
    Shete A; Shaikh A; Nayeem KJ; Rodrigues L; Ali MS; Shah P; Khanna R; Majid S; Rasheed SA; Shaikh S; Rahman T
    World J Diabetes; 2013 Dec; 4(6):358-64. PubMed ID: 24379927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
    Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes.
    Nagayama D; Kawana H; Watanabe Y; Horikawa O; Ohira M; Saiki A
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis.
    Ito H; Mifune M; Matsuyama E; Furusho M; Omoto T; Shinozaki M; Nishio S; Antoku S; Abe M; Togane M; Koga S; Sanaka T
    Diabetes Ther; 2013 Dec; 4(2):321-9. PubMed ID: 23801219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.
    Ito D; Inoue K; Kaneko K; Yanagisawa M; Sumita T; Ikegami Y; Awata T; Ishida H; Katayama S; Inukai K
    J Clin Med Res; 2015 May; 7(5):303-7. PubMed ID: 25780477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B; Foley JE; Bosi E
    Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
    Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
    Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
    Lüdemann J; Dütting ED; Dworak M
    Ther Adv Endocrinol Metab; 2015 Aug; 6(4):141-8. PubMed ID: 26301063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
    Blüher M; Kurz I; Dannenmaier S; Dworak M
    World J Diabetes; 2012 Sep; 3(9):161-9. PubMed ID: 23125906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study.
    Hummel S; Beyerlein A; Pfirrmann M; Hofelich A; Much D; Hivner S; Bunk M; Herbst M; Peplow C; Walter M; Kohn D; Hummel N; Kratzsch J; Hummel M; Füchtenbusch M; Hasford J; Ziegler AG;
    Mol Metab; 2018 Mar; 9():168-175. PubMed ID: 29396374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study.
    Kim NH; Kim DL; Kim KJ; Kim NH; Choi KM; Baik SH; Kim SG
    Endocrinol Metab (Seoul); 2017 Jun; 32(2):241-247. PubMed ID: 28685513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
    Odawara M; Sagara R
    J Diabetes Metab Disord; 2015; 15():21. PubMed ID: 27382546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.